YAMAUCHI Takahiro

FacultyGeneral Medicine, Hematology and Cardiology
Teacher OrganizationGeneral Medicine
Education and
 Research Organization
Faculty of Medical Sciences, School of Medicine
PositionProfessor
Last Updated: 18/12/11 14:23

Researcher Profile & Settings

Name

    YAMAUCHI Takahiro

Affiliation

  •  General Medicine, Hematology and Cardiology Professor

Education

  • Apr. 1992Mar. 1996Fukui Medical School 生態系
  • Apr. 1983Mar. 1989Fukui Medical School

Academic & Professional Experience

  • Jan. 19962003- Assistant Professor, University of Fukui, 2001-2003 Assistant Professor, Fukui Medical University 1999-2001 postdoctoral fellow, MD Anderson Cancer Center 1996-1999 Assistant Professor, Fukui Medical University 1992-1996 Graduate students, Fukui Medical University

Overseas travel history

  • 米国 MD Anderson Cancer Center Mar.  1999- Sep. 2001

Research Activities

Published Papers

Conference Activities & Talks

  • Using Rasburicase for tumor lysis syndrome with hematological malignancies and electrolytic changes
     Oct.  2016
  • Peripheral monocytosis as an initial presentation in a patient with diffuse large B cell lymphoma
    M.Matsumoto,Y.Matsuda,I.Sakamaki,H.Tsukasaki,Y.Yamamoto,K.Oiwa,K.Itoh,K.Tai,N.Hosono,S.Kishi,T.Yamauchi.
     Oct.  2016
  • Two cases of cryptococcosis with hematological malignancies diagnosed by blood culture.
    K Ito,H Iwasaki,K Tai,H Shigemi,I Sakamaki,T Ueda,T Yamauchi.
     Oct.  2016
  • The risk factors of tumor lysis syndrome in symptomatic myeloma treated with new agents
    K Oiwa,S Kishi,M Morita,M Ookura,T Tasaki,Y Matsuda,K Tai,N Hosono,T Ueda,T Yamauchi.
     Jul.  2016
  • The clinical characteristics of t-MDS/t-AML; 18 cases of single institution experience
    Y.Yamamoto,N.Hosono,H.Tsukasaki,K.Oiwa,K.Ito,M.Ookura,T.Tasaki,Y.Matsuda,K.Tai,I.Sakamaki,S.Ikegaya,S.Kishi,Y.Urasaki,A.Yoshida,T.Ueda,T.Yamauchi.
     Oct.  2016
  • Survivin inhibitor YM155 exerts potent cytotoxicity against quiescent (G0/G1) myeloma cells
    M.Ookura,S.Kishi,T.Yamauchi,T.Ueda,A.Yoshida.
     Oct.  2016
  • Prediction for poor mobilization of PBSC in patients with hematological malignancy
    K.Oiwa,S.Kishi,R.Matsumoto,H.Tsukasaki,Y.Yamamoto,K.Ito,M.Ookura,T.Tasaki,M.Morita,Y.Matsuda,K.Tai,N.Hosono,S.Ikegaya,I.Sakamaki,Y. Urasaki,A.Yoshida,H.Iwasaki,T.Ueda,T.Yamauchi.
     Oct.  2016
  • Diagnostic value of presepsin for early detection of bacterial infection in hematological diseases
    H.Tsukasaki,K.Ito,K.Tai,Y.Yamamoto,K.Oiwa,Y.Matsuda,N.Hosono,S.Ikegaya,I.Sakamaki,S.Kishi,Y.Urasaki,H.Iwasaki,T.Yamauchi.
     Oct.  2016
  • The Good Correlation between Amp-CML and International Scale by RQ-PCR in the patients with CML.-A single institution experience
    M.Ookura,N.Hosono,Y.Matsuda,K.Tai,I.Sakamaki,S.Kishi,Y.Urasaki,T.Yamauchi.
     May  2016
  • Tetracyclines modulate cytokine production and induce autophagy in THP-1 cells.
    H.Shigemi,K.Itoh,K.Tai,Y.Fujitomo,T.Yamauchi,H.Iwasaki.
    International meeting of Emerging Diseases and Surveillence (IMED) 2016 Nov.  2016
  • Clear correlation between reduction of WT1 and the efficacy of Azacitidine.
    N.Hosono,H.Tsukasaki,Y.Yamamoto,K.Oiwa,K.Ito,M.Ookura,T.Tasaki,Y.Matsuda,K.Tai,I.Sakamaki,S.Ikegaya,S.Kishi,Y.Urasaki,T.Ueda,T.Yamauchi.
     Oct.  2016
  • Decitabine induced the cell differentiation, decreased malignant potential, and increased susceptibility to apoptosis via a death receptor pathway with hypomethylation of MS4A3, PAR-4, APITD1, LOX in myelodysplastic syndrome cell line, MDS-L.
    Rie Nishi, Takahiro Yamauchi, Miyuki Ookura,, Yasufumi Matsuda, Toshiki Tasaki, Kaoru Tohyama, Takanori Ueda
     Dec.  2014
  • Phase I Trial of Volasertib, a Polo-like Kinase Inhibitor, in Japanese Patients with Acute Myeloid Leukemia
    Takahiro Yamauchi, Yukio Kobayashi, Hitoshi Kiyoi, Toru Sakura, Tomoko Hata, Kiyoshi Ando, Aiko Watabe, Akiko Harada, Yasushi Miyazaki, Tomoki Naoe
     Nov.  2014
  • Single institute retrospective analysis of febuxostat for management of tumor lysis syndrome with hematological malignancies
    Mihoko Takai, Takahiro Yamauchi, Miyuki Ookura, Hiroaki Araie, Toshiki Tasaki, Yasufumi Matsuda, Katsunori Tai, Satoshi Ikegaya, Shinji Kishi, Akira Yoshida, Yoshimasa Urasaki, Takanori Ueda
     Nov.  2014
  • Panobinostat and ponatinib show synergistic cytotoxicity against imatinib-resistant CML cell lines
    Yasufumi Matsuda, 山内 高弘, Mihoko Takai, Eiju Negoro, Koji Morinaga, Hiroko Shigemi, Kanako Uzui, Rie Nishi, Shinya Kimura, Taira Maekawa, Takanori Ueda
     Nov.  2014
  • Olaparib enhances the cytotoxicity of gemtuzumab ozogamicin against CD33-positive myeloid leukemia cells
    Takahiro Yamauchi, Kanako Uzui, Mihoko Takai, Yasufumi Matsuda, Takanori Ueda
     Sep.  2014
  • Prognostic influence of blood cell counts of patients with advanced diffuse large B cell lymphoma treated with R-CHOP.
    Takahiro Yamauchi, Toshiki Tasaki, Katsunori Tai, Satoshi Ikegaya, Shinji Kishi, Eiju Negoro, Akira Yoshida, Hiromichi Iwasaki, Takanori Ueda
     Jul.  2014
  • THE COMBINATION OF PANOBINOSTAT AND PONATINIB EXERTS SYNERGISTIC CYTOTOXICITY IN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA CELL LINES INCLUDING BCR-ABL GENE MUTATION WITH T315I
    Yasufumi Matsuda, Takahiro Yamauchi, Mihoko Takai, Hiroko Shigemi, Kanako Uzui, Rie Nishi, Shinya Kimura, Taira Maekawa, Takanori Ueda
     Jun.  2014
  • Newly established nelarabine-resistant leukemic cell line is insensitive to forodesine
    Takahiro Yamauchi, Kanako Uzui, Takanori Ueda
    JSH International symposium, Hamamatsu Japan May  2014
  • YM155 Exerts Potent Cytotoxic Activity Against Quiescent (G0/G1) Multiple Myeloma and Bortezomib Resistant Cells Via Inhibition of Mcl-1 and Survivin
    M.Ookura,T.Fujii,S.Kishi,H.Shigemi,N.Hosono, T.Yamauchi,T.Ueda,A.Yoshida
    57th ASH Annual Meeting Dec.  2015
  • The PS and the time to the first relapse predicts outcome for patients with relapsed DLBCL
     Oct.  2015
  • The risk factors of tumor lysis syndrome in patients with multiple myeloma
     Oct.  2015
  • Survivin inhibitor YM155 overcomes the resistance to bortezomib in multiple myeloma
     Oct.  2015
  • Prognostic significance of epigenetic silencing of BIM in aggressive non-Hodgkin lymphoma
     Oct.  2015
  • Reversal of bortezomib resistance in myeloma cells by Ixazomib in combination with HSP90 inhibitor
     Oct.  2015
  • Decitabine Induces Cell Differentiation and Growth Inhibition, which Accompanies Up-regulation of PRKC apoptosis WT1 regulator (PAWR) protein and Down-regulation of WT1 in Myelodysplastic Syndrome Cell Line, MDS-L
    N.Hosono,R.Nishi,T.Yamauchi,K.Tohyama,T.Ueda
    The 6th JSH International Symposium May  2015
  • Decitabine Induced Cell Differentiation of MDS cell line with the Reduction of WT1 Expression Level and HSP70
    R.Nishi,N.Hosono,M.Ookura,K.Tohyama,T.Ueda,T.Yamauchi
     Oct.  2015
  • The estimation of hemoglobin level in auto transfusion of BMT donor
    浦崎 芳正, 田居 克規, 根来 英樹, 細野 奈穂子, 松田 安史, 森田 美穂子, 多崎 俊樹, 大蔵 美幸, 伊藤 和広, 新家 裕朗, 岸 慎治, 山内 高弘, 上田 孝典, 岩崎 博道
     Oct.  2015
  • A case of successful treatment of hepatosplenic fungal abscesses in a patient with acute myeloid leukemia
    K.Tai,H.Iwasaki,S.Ikegaya,T.Yamauchi
     Oct.  2015